AbbVie acquires Apogee Therapeutics for $10.9 billion to boost immunology pipeline
On June 22, 2026, AbbVie announced the acquisition of clinical-stage biotech Apogee Therapeutics for $10.9 billion in cash, a 49-60% premium over its market value. The deal centers on Apogee’s lead drug candidate zumilokibart, an IL-13-targeting antibody for atopic dermatitis and asthma with potential twice-yearly dosing. This is AbbVie’s largest acquisition since 2019, aimed at offsetting declining Humira sales and strengthening its immunology portfolio amid biosimilar competition. The transaction is expected to close in Q3 2026 and become accretive by 2032.
Cross-source coverage
Wire timeline
AbbVie Acquires Apogee Therapeutics for $10.9 Billion, Boosting Immunology Pipeline
On June 22, 2026, AbbVie announced a definitive agreement to acquire Apogee Therapeutics for $10.9 billion ($135.11 per share in cash), a 49.5% premium. Apogee's stock surged 46% while AbbVie shares rose 6.25%. The acquisition strengthens AbbVie's immunology portfolio beyond existing drugs Skyrizi and Rinvoq, which generated $7.3 billion in combined Q1 revenue. Apogee's lead candidate zumilokibart, a long-acting monoclonal antibody targeting IL-13 for atopic dermatitis and asthma, is in Phase 2/3 development. AbbVie aims to extend its immunology leadership as Humira faces biosimilar competition. The deal is seen as a strategic move to diversify revenue streams and sustain long-term growth.
Yahoo FinanceApogee Therapeutics Hits Fresh High on AbbVie $10.9B Merger
Apogee Therapeutics (APGE) surged to an all-time high after AbbVie announced a definitive agreement to acquire the company for $10.9 billion. Under the deal, AbbVie will purchase all APGE shares at $135.11 each, a 49.5% premium over the prior closing price. Shares rose 46.66% to close at $132.55. The acquisition aims to strengthen AbbVie's immunology portfolio with Apogee's pipeline targeting dermatologic, respiratory, and inflammatory diseases. The transaction is subject to regulatory and shareholder approvals and is expected to close in Q3 2026.
Yahoo FinanceAbbVie's $10.9 Billion Apogee Deal Will Extend Its Immunology Dominance: Is It Time to Load Up on This Dividend King?
AbbVie (ABBV) announced a $10.9 billion acquisition of Apogee Therapeutics (APGE), paying $135.11 per share in cash, a 47% premium. The deal, unanimously approved by both boards, is expected to close in Q3 2026. Apogee is a clinical-stage biotech with promising immunology drugs, including zumilokibart for eczema and asthma, which offers longer dosing intervals. AbbVie expects the acquisition to be accretive to non-GAAP EPS starting in 2032. AbbVie's stock rose over 6% on the announcement, reinforcing its dominance in the immunology market.
Yahoo Finance$11 Billion AbbVie-Apogee Deal Drives Stock Rally on Drug Pipeline Promise
AbbVie shares surged on June 22, 2026, after announcing a $10.9 billion all-cash acquisition of Apogee Therapeutics at $135 per share, a 50% premium. The deal centers on Apogee's lead asset, Zumilokibart (APG777), an IL-13 inhibitor showing strong efficacy in atopic dermatitis and asthma, with Phase 2 data achieving full skin clearance in 16.5% of patients and potential to outperform competitors like Dupixent. Analysts project $5.2 billion peak sales for the drug. Additionally, Apogee's technology enables dosing every 3-6 months, improving patient compliance. The deal also includes APG273, a combination therapy for asthma. AbbVie aims to protect market share amid patent cliffs. Wall Street maintains a 'Moderate Buy' rating with a $251 price target, implying 10% upside, and AbbVie offers a 3.01% dividend yield.
Yahoo FinanceAbbVie to Acquire Apogee Therapeutics for $10.9 Billion to Boost Immunology Pipeline
AbbVie has agreed to acquire Apogee Therapeutics, a biotechnology company based in Waltham, Massachusetts, for approximately $10.9 billion in cash, paying $135.11 per share. This represents a 49% premium over Apogee's closing price prior to the announcement. The acquisition is intended to strengthen AbbVie's core immunology franchise by adding Apogee's experimental drug zumilokibart, a potential treatment for the most common form of eczema. The deal ranks among the largest in the pharmaceutical industry so far this year. The news was reported by the Wall Street Journal on Yahoo Finance, dated June 23, 2026.
Yahoo FinanceAbbVie to Buy Apogee Therapeutics for $10.9 Billion to Boost Immunology Pipeline
Pharmaceutical giant AbbVie has agreed to acquire Apogee Therapeutics, a biotechnology company based in Waltham, Massachusetts, for approximately $10.9 billion. The deal, announced on Monday, will be an all-cash transaction at $135.11 per share, representing a 49% premium over Apogee's closing price on the prior Thursday. The acquisition aims to strengthen AbbVie's immunology franchise by adding Apogee's experimental drug zumilokibart, a potential treatment for the most common form of eczema. This represents one of the largest industry deals so far in 2026.
Yahoo FinanceAbbVie to acquire Apogee Therapeutics in $10.9 billion deal
AbbVie announced on June 22, 2026, that it will acquire Apogee Therapeutics in an all-cash transaction valued at approximately $10.9 billion, or $135.11 per share. The deal, approved by both companies' boards, is expected to close in Q3 2026. The acquisition adds clinical-stage therapies for inflammatory and immunological diseases to AbbVie's portfolio. Apogee's lead candidate is zumilokibart, an anti-IL-13 monoclonal antibody for atopic dermatitis. Phase 2 data showed about two-thirds of treated patients achieved significant skin clearance after 16 weeks. Apogee is also developing APG273, a combination therapy for asthma. AbbVie expects the deal to be accretive to adjusted earnings per share from 2032.
Yahoo FinanceAbbVie Strikes $10.9 Billion Deal for Apogee to Strengthen Future Immunology Portfolio
AbbVie announced a $10.9 billion acquisition of Apogee Therapeutics on June 22, 2026, its largest deal in over five years. The acquisition gives AbbVie control of zumilokibart, an experimental therapy for inflammatory diseases like atopic dermatitis and asthma, potentially competing with Sanofi and Regeneron's Dupixent. The $135.11 per share offer represents a 49.49% premium, causing Apogee shares to surge 47% in premarket trading. Analysts view the deal as strategically logical, positioning AbbVie to strengthen its immunology portfolio as it faces patent expirations on Humira and future challenges to Skyrizi and Rinvoq. The transaction follows AbbVie's prior acquisitions of ImmunoGen and Cerevel Therapeutics. If approved, zumilokibart's every-three-to-six-month dosing schedule could become a key competitive advantage. AbbVie expects the deal to close in Q3 2026 and contribute positively to adjusted EPS starting in 2032.
Yahoo FinanceAbbVie Acquires Apogee Therapeutics for $10.9 Billion to Boost Immunology Pipeline
AbbVie has agreed to acquire Apogee Therapeutics for $135.11 per share in cash, valuing the clinical-stage biotechnology company at approximately $10.9 billion. The deal, approved by both boards, is expected to close in the third quarter of 2026. It centers on Apogee's lead drug candidate, zumilokibart, an antibody targeting IL-13 for conditions like atopic dermatitis and asthma. Phase 2 trials showed roughly two-thirds of patients achieved significant skin clearance at 16 weeks, with maintenance dosing as infrequent as twice a year, offering a potential convenience advantage over Sanofi and Regeneron's Dupixent. Apogee's pipeline also includes a combination therapy for asthma. AbbVie expects adjusted earnings per share to decrease by 14 cents in 2026 and 46 cents in 2027 before the acquisition becomes accretive in 2032. Morgan Stanley advised AbbVie, while Jefferies and Goldman Sachs advised Apogee.
Yahoo FinanceAbbVie to Acquire Apogee Therapeutics for $10.9 Billion
AbbVie has announced an agreement to acquire Apogee Therapeutics for $135.11 per share in cash, valuing the clinical-stage biotechnology company at approximately $10.9 billion. The deal, approved by both boards, is expected to close in Q3 2026, pending regulatory and shareholder approval. The acquisition centers on Apogee's lead drug candidate, zumilokibart, an IL-13 antibody targeting atopic dermatitis and asthma. Phase 2 trials showed about two-thirds of patients achieved significant skin clearance at 16 weeks, with a maintenance schedule as infrequent as twice a year, offering a potential convenience advantage over Sanofi and Regeneron's Dupixent. AbbVie projects the acquisition will be accretive by 2032, with adjusted earnings impacts of about 14 cents in 2026 and 46 cents in 2027. Morgan Stanley advised AbbVie, while Jefferies and Goldman Sachs advised Apogee.
Yahoo FinanceAbbVie Nears $10.9 Billion Deal for Apogee Therapeutics in Major Acquisition Push
AbbVie is close to acquiring Apogee Therapeutics for $10.9 billion in cash, a roughly 60% premium over its market value, according to a Reuters report. The deal would be AbbVie's largest since the 2019 Allergan acquisition. Apogee, a clinical-stage biotech with no approved products, is developing the antibody drug zumilokibart for inflammatory diseases like atopic dermatitis, showing promise with twice-yearly dosing. AbbVie's move reflects its need for new growth drivers as its Humira franchise declines due to biosimilar competition, despite strong performance from Skyrizi and Rinvoq. An announcement could come as early as June 22.
Yahoo FinanceAbbVie nears $10.9 billion acquisition of Apogee Therapeutics
AbbVie (ABBV) is close to acquiring Apogee Therapeutics for $10.9 billion in cash, a roughly 60% premium to Apogee's share price, according to a Reuters report. The deal, expected as early as June 22, would be AbbVie's largest since its 2019 Allergan merger. Apogee is a clinical-stage biotech with no marketed products; its lead candidate zumilokibart targets IL-13 for atopic dermatitis and has shown potential for twice-yearly dosing. The acquisition comes as AbbVie seeks new growth drivers beyond its immunology portfolio of Skyrizi, Rinvoq, and the declining Humira. The $10.9 billion price values Apogee well above its $6.8 billion market cap, reflecting premium for future potential. Apogee recently secured up to $1.3 billion from Blackstone Life Sciences for Phase 3 trials and potential launch.
Yahoo Finance